ECONOMIC EVALUATION OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED RENAL-CELL CARCINOMA IN JAPAN

被引：0
|
作者：
Maeda, T. [1 ]
Morimoto, K. [2 ]
Mo, X. [3 ]
Moriwaki, K. [4 ]
Shimozuma, K. [5 ]
机构：
[1] Keio Univ, Fujisawa, Kanagawa, Japan
[2] Kyoto Univ, Kyoto, Japan
[3] Ritsumeikan Univ, Osaka 27, Japan
[4] Ritsumeikan Univ, Kyoto 26, Japan
[5] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC280
引用
收藏
页码：S188 / S189
页数：2
相关论文
共 50 条
  • [1] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
    Gunjur, Ashray
    [J]. LANCET ONCOLOGY, 2018, 19 (05): : E232 - E232
  • [2] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Frontera, O. Aren
    Melichar, B.
    Choueiri, T. K.
    Plimack, Elizabeth R.
    Barthelemy, P.
    Porta, C.
    George, S.
    Powles, T.
    Donskov, F.
    Neiman, V.
    Kollmannsberger, C. K.
    Salman, P.
    Gurney, H.
    Hawkins, R.
    Ravaud, A.
    Grimm, M. -O.
    Bracarda, S.
    Barrios, C. H.
    Tomita, Y.
    Castellano, D.
    Rini, B. I.
    Chen, A. C.
    Mekan, S.
    McHenry, M. B.
    Wind-Rotolo, M.
    Doan, J.
    Sharma, P.
    Hammers, H. J.
    Escudier, B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14): : 1277 - 1290
  • [3] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19): : 1767 - 1778
  • [4] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Gervaso, Lorenzo
    Fazio, Nicola
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (05): : 476 - 477
  • [5] Re: Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma
    Powles, Tom
    [J]. EUROPEAN UROLOGY, 2018, 74 (05) : 679 - 680
  • [6] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
    Cerrato, Clara
    Pradere, Benjamin
    Mir, Maria Carmen
    [J]. EUROPEAN UROLOGY, 2023, 84 (04) : E93 - E93
  • [7] FDA Approves Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (05) : 387 - 387
  • [8] Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
    Wu, Bin
    Zhang, Qiang
    Sun, Jie
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [9] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
  • [10] UNISON: Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602)
    Gedye, Craig
    Pook, David William
    Krieger, Laurence Eliot Miles
    Harris, Carole A.
    Goh, Jeffrey C.
    Kichenadasse, Ganessan
    Gurney, Howard
    Underhill, Craig
    Parnis, Francis
    Joshua, Anthony M.
    Ferguson, Thomas
    Roncolato, Felicia
    Harrison, Michelle L.
    Morris, Michelle Frances
    Begbie, Stephen
    Hovey, Elizabeth J.
    George, Mathew
    Prithviraj, Prashanth
    Liow, Elizabeth Chien Hern
    Davis, Ian D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345